FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3183969300> ?p ?o ?g. }

• W3183969300 endingPage "e2118475" @default.
• W3183969300 startingPage "e2118475" @default.
• W3183969300 abstract "Although bevacizumab is a standard of care in combination treatments for metastatic colorectal cancer (mCRC), its clinical benefit has been limited.To determine whether sequential scheduling of bevacizumab administration in combination with chemotherapy improves treatment efficacy in patients with mCRC, in keeping with the tumor vascular normalization hypothesis.This open-label, randomized clinical phase 3 trial was conducted from May 8, 2012, to December 9, 2015, at 3 Italian centers. Patients aged 18 to 75 years with unresectable, previously untreated, or single line-treated mCRC were recruited. Follow-up was completed December 31, 2019, and data were analyzed from February 26 to July 24, 2020.Patients received 12 biweekly cycles of standard oxaliplatin-based regimens (modified FOLFOX-6 [levo-folinic acid, fluorouracil, and oxaliplatin]/modified CAPOX [capecitabine and oxaliplatin]) plus bevacizumab administered either on the same day as chemotherapy (standard arm) or 4 days before chemotherapy (experimental arm).The primary end point was the objective response rate (ORR) measured with Response Evaluation Criteria in Solid Tumors, version 1.1. Secondary end points included progression-free survival, overall survival, safety, and quality of life (QOL).Overall, 230 patients (136 men [59.1%]; median age, 62.3 [interquartile range, 53.3-67.6] years) were randomly assigned to the standard arm (n = 115) or the experimental arm (n = 115). The median duration of follow-up was 68.3 (95% CI, 61.0-70.0) months. No difference in ORR (57.4% [95% CI, 47.8%-66.6%] in the standard arm and 56.5% [95% CI, 47.0-65.7] in the experimental arm; P = .89) or progression-free survival (10.5 [95% CI, 9.1-12.3] months in the standard arm and 11.7 [95% CI, 9.9-12.9] months in the experimental arm; P = .15) was observed. However, the median overall survival was 29.8 (95% CI, 22.5-41.1) months in the experimental arm compared with 24.1 (95% CI, 18.6-29.8) months in the standard arm (adjusted hazard ratio, 0.73; 95% CI, 0.54-0.99; P = .04). Moreover, the experimental arm was associated with a significant reduction in the rate of severe diarrhea (6 [5.3%] vs 19 [16.5%]; P = .006) and nausea (2 [1.8%] vs 8 [7.0%]; P = .05) and improved physical functioning (mean [SD] change from baseline, 0.65 [1.96] vs -7.41 [2.95] at 24 weeks; P = .02), and constipation scores (mean [SD] change from baseline, -17.2 [3.73] vs -0.62 [4.44]; P = .003).In this randomized clinical trial, sequential administration of bevacizumab plus chemotherapy did not improve ORR, the primary end point. However, the overall survival advantage, fewer adverse effects, and better health-related QOL associated with sequential bevacizumab administration might provide the basis for exploring antiangiogenic combination treatments with innovative perspectives.EudraCT Identifier: 2011-004997-27; ClinicalTrials.gov Identifier: NCT01718873." @default.
• W3183969300 created "2021-08-02" @default.
• W3183969300 creator A5005851993 @default.
• W3183969300 creator A5006309105 @default.
• W3183969300 creator A5014792832 @default.
• W3183969300 creator A5016655393 @default.
• W3183969300 creator A5016966886 @default.
• W3183969300 creator A5023024840 @default.
• W3183969300 creator A5034347320 @default.
• W3183969300 creator A5035669120 @default.
• W3183969300 creator A5038665049 @default.
• W3183969300 creator A5040685164 @default.
• W3183969300 creator A5042758138 @default.
• W3183969300 creator A5048826974 @default.
• W3183969300 creator A5058691292 @default.
• W3183969300 creator A5062149201 @default.
• W3183969300 creator A5062538462 @default.
• W3183969300 creator A5063093846 @default.
• W3183969300 creator A5065270981 @default.
• W3183969300 creator A5068999228 @default.
• W3183969300 creator A5071355854 @default.
• W3183969300 creator A5074752423 @default.
• W3183969300 creator A5082691214 @default.
• W3183969300 creator A5085096826 @default.
• W3183969300 creator A5088304855 @default.
• W3183969300 creator A5089152448 @default.
• W3183969300 creator A5089737234 @default.
• W3183969300 creator A5091003529 @default.
• W3183969300 date "2021-07-26" @default.
• W3183969300 modified "2023-10-14" @default.
• W3183969300 title "Effect of Bevacizumab in Combination With Standard Oxaliplatin-Based Regimens in Patients With Metastatic Colorectal Cancer" @default.
• W3183969300 cites W1697331515 @default.
• W3183969300 cites W1947168884 @default.
• W3183969300 cites W1971211622 @default.
• W3183969300 cites W1977887541 @default.
• W3183969300 cites W1978139448 @default.
• W3183969300 cites W1989402742 @default.
• W3183969300 cites W1993780950 @default.
• W3183969300 cites W2000292756 @default.
• W3183969300 cites W2000657685 @default.
• W3183969300 cites W2005348280 @default.
• W3183969300 cites W2006202974 @default.
• W3183969300 cites W2010300658 @default.
• W3183969300 cites W2041130945 @default.
• W3183969300 cites W2048067273 @default.
• W3183969300 cites W2084740377 @default.
• W3183969300 cites W2105683151 @default.
• W3183969300 cites W2110977364 @default.
• W3183969300 cites W2112669537 @default.
• W3183969300 cites W2120009106 @default.
• W3183969300 cites W2125447919 @default.
• W3183969300 cites W2131783235 @default.
• W3183969300 cites W2132416992 @default.
• W3183969300 cites W2143743735 @default.
• W3183969300 cites W2147634187 @default.
• W3183969300 cites W2158303916 @default.
• W3183969300 cites W2162158906 @default.
• W3183969300 cites W2273538304 @default.
• W3183969300 cites W2331318007 @default.
• W3183969300 cites W2344732859 @default.
• W3183969300 cites W2470575266 @default.
• W3183969300 cites W2555650158 @default.
• W3183969300 cites W2601414401 @default.
• W3183969300 cites W2784207302 @default.
• W3183969300 cites W2898109351 @default.
• W3183969300 cites W2913797367 @default.
• W3183969300 cites W2986238534 @default.
• W3183969300 cites W2998951754 @default.
• W3183969300 cites W3003714437 @default.
• W3183969300 cites W3009139795 @default.
• W3183969300 cites W3017100631 @default.
• W3183969300 cites W4240399716 @default.
• W3183969300 cites W4252372801 @default.
• W3183969300 cites W4252851641 @default.
• W3183969300 cites W4252902715 @default.
• W3183969300 cites W4253036856 @default.
• W3183969300 doi "https://doi.org/10.1001/jamanetworkopen.2021.18475" @default.
• W3183969300 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8314140" @default.
• W3183969300 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34309665" @default.
• W3183969300 hasPublicationYear "2021" @default.
• W3183969300 type Work @default.
• W3183969300 sameAs 3183969300 @default.
• W3183969300 citedByCount "11" @default.
• W3183969300 countsByYear W31839693002022 @default.
• W3183969300 countsByYear W31839693002023 @default.
• W3183969300 crossrefType "journal-article" @default.
• W3183969300 hasAuthorship W3183969300A5005851993 @default.
• W3183969300 hasAuthorship W3183969300A5006309105 @default.
• W3183969300 hasAuthorship W3183969300A5014792832 @default.
• W3183969300 hasAuthorship W3183969300A5016655393 @default.
• W3183969300 hasAuthorship W3183969300A5016966886 @default.
• W3183969300 hasAuthorship W3183969300A5023024840 @default.
• W3183969300 hasAuthorship W3183969300A5034347320 @default.
• W3183969300 hasAuthorship W3183969300A5035669120 @default.
• W3183969300 hasAuthorship W3183969300A5038665049 @default.
• W3183969300 hasAuthorship W3183969300A5040685164 @default.
• W3183969300 hasAuthorship W3183969300A5042758138 @default.
• W3183969300 hasAuthorship W3183969300A5048826974 @default.

• next